Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

Clinical Breast Cancer

Volumn 9, Issue SUPPL.2, 2009, Pages

  Anders, Carey K ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like breast cancer; BRCA1; BSI 201; Cetuximab; Cytokeratin 5 6; PARP1

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AZD 2881; BEVACIZUMAB; BRCA1 PROTEIN; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN;

AGE; BREAST CANCER; BREAST FEEDING; DIARRHEA; DNA REPAIR; DRUG DOSE REDUCTION; DRUG MECHANISM; FATIGUE; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; GENE MUTATION; HUMAN; LOADING DRUG DOSE; METASTASIS; MULTIPARA; ONCOGENE; PROGNOSIS; REVIEW; RISK FACTOR; WAIST HIP RATIO; BREAST TUMOR; FEMALE; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 70249123890     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.s.008     Document Type: Article

References (61)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
3. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
4. Swain SM. Triple-negative breast cancer: metastatic risk and role of platinum agents. Paper presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL.
5. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
6. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
7. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-40.
8. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44.
9. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer 2007;9:R65.
10. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
11. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-94.
12. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002;2:113-23.
13. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
14. Arnes JB, Brunet J-S, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11:4003-11.
15. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
16. Laakso M, Loman N, Borg å, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-8.
17. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
18. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-8.
19. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
20. Millikan RC, Newman B, Tse C-K, et al. Epidemiology of basal-like breast cancer [published erratum in: Breast Cancer Res Treat 2008;109:141].
21. Breast Cancer Res Treat 2008;109:123-39.
22. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
23. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
24. Collett K, Stefansonn IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14:1108-12.
25. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
26. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
27. Heitz F, Harter P, Traut A, et al. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 2008;26(15 suppl) :43s (abstract 1010).
28. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638-45.
29. Niwinska A, Murawska M. Brain metastases in breast cancer patients: differences in survival depending on biological subtype and RPA RTOG prognostic class. J Clin Oncol 2008;26(15 suppl) :55s (abstract 1056).
30. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7.
31. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
32. Rouzier R, Perou CM, Symmans W F, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
33. Hayes D F, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007;357:1496-506.
34. Hudis C, Citron M, Berry D, et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 2005;94(suppl 1):S20 (abstract 41).
35. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
36. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
37. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008;26(15 suppl) :43s (abstract 1009).
38. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in "triple-negative" breast cancer (BC). Breast Cancer Res Treat 2006;100(suppl 1): S149 (abstract 3074).
39. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007;106(suppl 1): S32 (abstract 308).
40. O'Shaughnessy J, Yoffe M, Osborne C, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. Cancer Res 2009;69(suppl) :194s (abstract 2120).
41. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33.
42. Troester MA, Herschkowitz JI, Oh DS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006;6:276.
43. Moyano J V, Evans JR, Chen F, et al. αB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116:261-70.
44. Sparano JA, Gray R, Goldstein LJ, et al. GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. Cancer Res 2009;69(suppl) :70s (abstract 25).
45. Keen JC, Yan L, Mack KM, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat 2003;81:177-86.
46. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
47. Miles D, Chan A, Romieu G, et al. Randomised, double-blind, placebo-controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC) : AVADO. J Clin Oncol 2008;26(15 suppl) :1008s (abstract LBA1011).
48. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008;26(15 suppl) :172s (abstract 3577).
49. Mahany JJ Jr, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008;26(15 suppl) :172s (abstract 3579).
50. Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res 2009;69(suppl) :242s (abstract 3118).
51. Lacevic M, Minton SE, Schmitt ML, et al. Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior anti-hormonal therapy. Breast Cancer Res Treat 2007;106(suppl 1):S117 (abstract 2097).
52. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741 [published erratum in: J Clin Oncol 2003;21:2226].
53. J Clin Oncol 2003;21:1431-9.
54. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52:25-33.
55. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase [published erratum in: Nature 2007;447:346].
56. Nature 2005;434:913-7.
57. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
58. Foulkes WD, Brunet J-S, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid- microvascularproliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
59. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201 a poly (ADP-ribose) polymerase-1 (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC) : results of a randomized phase II trial. J Clin Oncol 2009;27(suppl) :793s (abstract 3).
60. Carey LA, Mayer E, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S32 (abstract 307).
61. Sabnis GJ, Gediya LK, Njar VCO, et al. HDAC inhibitors sensitize ER negative breast cancer cells to AIs. Breast Cancer Res Treat 2007;106(suppl 1):S117 (abstract 2096).